Literature DB >> 30293095

Prevalence and predictors of atrial arrhythmias in patients with sinus node dysfunction and atrial pacing.

Abdallah Bukari1, Eisha Wali1, Amrish Deshmukh1, Zaid Aziz1, Michael Broman1, Andrew Beaser1, Gaurav Upadhyay1, Hemal Nayak1, Roderick Tung1, Cevher Ozcan2.   

Abstract

PURPOSE: This study aimed to determine the incidence, prevalence, and predictors of atrial arrhythmias (AAs) in patients with symptomatic sinus node dysfunction (SND) who required permanent pacemaker implantation. Also, we evaluated the impact of atrial pacing (AP) on AAs.
METHODS: All consecutive patients who underwent pacemaker implantation from 2005 to 2011 were included. Atrial fibrillation (AF), atrial flutter (AFL), atrial tachycardia (AT), and AV nodal reentrant tachycardia (AVNRT) were detected via pacemaker interrogation and clinical documentation.
RESULTS: The study group included 322 patients (44% male) with mean age 68.8 ± 15 years and followed for an average of 5.6 ± 2.2 years (median 5.7 years). Overall, 61.8% were found to have any AA at follow-up. Individual prevalence of AAs was high as follows: AF 43.5%, AFL 6.5%, AT 25%, and AVNRT 6.8%. AF was documented in 23% of patients (n = 74) prior to pacemaker; among those, 15% (n = 11) had no recurrence of AF with average AP of 74%. The incidence of new-onset AF after pacemaker was 15.8%. In subgroup analysis, prevalence of AF was increased by 16% with high rate of AP (81-100%) and 17% with lower rate of AP (0-20%). Incidence of new-onset AF was not affected by AP. Diabetes, hypertension, and left atrial enlargement were predictors of AAs. White men and women had higher prevalence of AF.
CONCLUSIONS: AAs are highly prevalent in SND, particularly in white patients. Paroxysmal AF is suppressed with AP in minority, but there is no impact of AP on new-onset AF. Patients with diabetes, hypertension, and dilated atria must be monitored closely for early detection of AAs.

Entities:  

Keywords:  Atrial arrhythmias; Atrial fibrillation; Pacemaker; Sinus node dysfunction

Mesh:

Year:  2018        PMID: 30293095      PMCID: PMC7134386          DOI: 10.1007/s10840-018-0463-7

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  26 in total

1.  Simultaneous occurrence of atrial fibrillation and atrial flutter.

Authors:  G Horvath; J J Goldberger; A H Kadish
Journal:  J Cardiovasc Electrophysiol       Date:  2000-08

2.  Prevalence and clinical implications of atrial fibrillation episodes detected by pacemaker in patients with sick sinus syndrome.

Authors:  H F Tse; C P Lau
Journal:  Heart       Date:  2005-03       Impact factor: 5.994

3.  The influence of atrial and ventricular pacing on the incidence of atrial fibrillation: a meta-analysis.

Authors:  Lior U Elkayam; Jodi L Koehler; Todd J Sheldon; Taya V Glotzer; Lawrence S Rosenthal; Gervasio A Lamas
Journal:  Pacing Clin Electrophysiol       Date:  2011-08-07       Impact factor: 1.976

4.  Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data.

Authors:  Jeffrey S Healey; William D Toff; Gervasio A Lamas; Henning R Andersen; Kevin E Thorpe; Kenneth A Ellenbogen; Kerry L Lee; Allan M Skene; Eleanor B Schron; J Douglas Skehan; Lee Goldman; Robin S Roberts; A John Camm; Salim Yusuf; Stuart J Connolly
Journal:  Circulation       Date:  2006-06-26       Impact factor: 29.690

5.  Pulmonary vein isolation for atrial fibrillation in patients with symptomatic sinus bradycardia or pauses.

Authors:  Yaariv Khaykin; Nassir F Marrouche; David O Martin; Walid Saliba; Robert Schweikert; Mark Wexman; Brian Strunk; Salwa Beheiry; Eduardo Saad; Mandeep Bhargava; J David Burkhardt; George Joseph; Patrick Tchou; Andrea Natale
Journal:  J Cardiovasc Electrophysiol       Date:  2004-07

6.  Atrial fibrillation after DDDR pacemaker implantation.

Authors:  Anne M Gillis; Margaret Morck
Journal:  J Cardiovasc Electrophysiol       Date:  2002-06

Review 7.  Inter-relationships of atrial fibrillation and atrial flutter mechanisms and clinical implications.

Authors:  Albert L Waldo; Gregory K Feld
Journal:  J Am Coll Cardiol       Date:  2008-02-26       Impact factor: 24.094

8.  Incidence of atrial fibrillation in whites and African-Americans: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Alvaro Alonso; Sunil K Agarwal; Elsayed Z Soliman; Marietta Ambrose; Alanna M Chamberlain; Ronald J Prineas; Aaron R Folsom
Journal:  Am Heart J       Date:  2009-07       Impact factor: 4.749

9.  Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses.

Authors:  Mélèze Hocini; Prashanthan Sanders; Isabel Deisenhofer; Pierre Jaïs; Li-Fern Hsu; Christophe Scavée; Rukshen Weerasoriya; Florence Raybaud; Laurent Macle; Dipen C Shah; Stéphane Garrigue; Philippe Le Metayer; Jacques Clémenty; Michel Haïssaguerre
Journal:  Circulation       Date:  2003-09-02       Impact factor: 29.690

10.  Ventricular pacing or dual-chamber pacing for sinus-node dysfunction.

Authors:  Gervasio A Lamas; Kerry L Lee; Michael O Sweeney; Russell Silverman; Angel Leon; Raymond Yee; Roger A Marinchak; Greg Flaker; Eleanor Schron; E John Orav; Anne S Hellkamp; Stephen Greer; John McAnulty; Kenneth Ellenbogen; Frederick Ehlert; Roger A Freedman; N A Mark Estes; Arnold Greenspon; Lee Goldman
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245

View more
  2 in total

1.  Sick Sinus Syndrome Can Be Associated with Postural Tachycardia Syndrome and Inappropriate Sinus Tachycardia Syndrome.

Authors:  Paul R Harnish; Pinang Shastri; Blair P Grubb
Journal:  J Innov Card Rhythm Manag       Date:  2021-05-15

2.  Relationship between Atrial Tachyarrhythmias and Intrathoracic Impedance in Patients with a Pacemaker and Preserved Ejection Fraction.

Authors:  Min-Tsun Liao; Chun-Kai Chen; Ting-Tse Lin; Li-Ying Cheng; Hong-Wen Ting; Rou-Fang Wang; Zhi-Jun Liu; Yen-Bin Liu
Journal:  J Clin Med       Date:  2019-12-31       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.